banter and General Discussion, page-9400

No I don't think so. More around assays new and old. This is kind of how I see how this process seems to have gone in the fullness of deep time, so far as the stock market views things Indeed long enough for people to move on and in from all kinds of sides.

FDA - Your assays are not up to scratch, they don't back up your assertions, or even your results.

MSB - Oh OK, maybe we could run another trial, for Adults. But first lets go cross check with other data we can use for assays from stored samples from the same batches against the trial outcomes.

MSB - Hmm, maybe it was faulty reagents coz when we test against stored batches results from all the assay methods correlate.

FDA - Oh, really? Truly? Well then we need to reassess this given efficacy from the last steroid refractory Pediatric aGVHD trial seems OK and especially so if this new data is accurate. Please send all of the info and we'll have a look again at whether or not a Biological Licensing Agreement can be applied to Ryoncil for this indication.

MSB - OK. We'll get right on to it.

Maybe there are some salient points I've missed but I did have a bout of chemo brain along the way so some things might have fallen off